Compare BUUU & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | ALLO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Hong Kong | United States |
| Employees | 16 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.8M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | BUUU | ALLO |
|---|---|---|
| Price | $12.66 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 22.3K | ★ 4.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $347.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.97 | $0.86 |
| 52 Week High | $20.76 | $2.80 |
| Indicator | BUUU | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 59.72 |
| Support Level | $6.84 | $1.01 |
| Resistance Level | $19.73 | $2.80 |
| Average True Range (ATR) | 1.82 | 0.18 |
| MACD | -0.45 | -0.01 |
| Stochastic Oscillator | 22.79 | 53.80 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.